We further show that this mechanism of NKA inhibition in human cancer cells is not restricted to plumbagin, but is shared by atovaquone, an FDA-approved anti-malarial agent, which also causes oxidative damage and is an excellent candidate for repurposing as a chemotherapeutic drug22,23. The gene discussed is TAC1; the disease is cancer.